Evidence map›Paper›PMID 25074521›Full record

ArticleNanoscale2014

Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors.

Patrick V Almeida, Mohammad-Ali Shahbazi, Ermei Mäkilä, Martti Kaasalainen, Jarno Salonen, Jouni Hirvonen, Hélder A Santos

Open access · hybridAbstract read
In one paragraph

Article in Nanoscale, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 115 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Chitosan Nanoparticle-Mediated Delivery ofAntioxidants (Basel, Switzerland) · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Patrick V AlmeidaDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, FI-00014 University of Helsinki, Finland. helder.santos@helsinki.fi.
Mohammad-Ali Shahbazi
Ermei Mäkilä
Martti Kaasalainen
Jarno Salonen
Jouni Hirvonen
Hélder A Santos
University of Helsinki · FIUniversity of Turku · FI

Funding

European Research Council 310892
6 · The paper itself

Abstract

Active targeting of nanoparticles to receptor-overexpressing cancer cells has great potential for enhancing the cellular uptake of nanoparticles and for reducing fast clearance of the nanoparticles from the body. Herein, we present a preparation method of a porous silicon (PSi)-based nanodelivery system for breast cancer targeting, by covalently conjugating a synthesized amide-modified hyaluronic acid (HA(+)) derived polymer on the surface of undecylenic acid-modified thermally hydrocarbonized PSi (UnTHCPSi) nanoparticles. The resulting UnTHCPSi-HA(+) nanoparticles showed relatively small size, reduced polydispersibility, high biocompatibility, improved colloidal and human plasma stability, as well as enhanced cellular interactions and internalization. Moreover, we demonstrated that the enhanced cellular association of UnTHCPSi-HA(+) relies on the capability of the conjugated HA(+) to bind and consequently target CD44 receptors expressed on the surface of breast cancer cells, thus making the HA(+)-functionalized UnTHCPSi nanoparticles a suitable and promising nanoplatform for the targeting of CD44-overexpressing breast tumors and for drug delivery.

Indexed as

Antineoplastic AgentsBiogenic AminesBreast NeoplasmsCell Line, TumorCell SurvivalDiffusionDrug CompoundingHumansHyaluronic AcidMaterials TestingNanocapsulesNanoconjugatesNanoporesParticle SizePorositySiliconAntineoplastic AgentsBiogenic AminesHyaluronic AcidNanocapsulesNanoconjugatesSilicon

Identifiers

PMID25074521
PMCPMC4234906
OpenAlexW2012927871

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.